China To De-link Indigenous Innovation And Public Procurement Policies - U.S.-China Strategic And Economic Dialogue
This article was originally published in PharmAsia News
Executive Summary
WASHINGTON - In a positive move for the life sciences industry and others conducting business in China, Chinese leaders have agreed to de-link indigenous innovation policies from government procurement, a decision that - if fully implemented - would provide a fairer competitive environment for foreign-invested enterprises in China
You may also be interested in...
Forced Technology Transfer Hinders Innovation In China – USTR
China still has major intellectual property enforcement problems that unfairly disadvantage U.S. IP rights holders in the country.
PharmAsia News Favorite Stories From 2011
If you missed some of the highlights of 2011, here’s your opportunity to check out some of our favorite stories from the year, as chosen by the editors of PharmAsia News.
Regulatory And Staffing Challenges For Private Hospitals In Southeast Asia - Private Healthcare World Asia 2011
SINGAPORE - Investor interest in Asia's private hospital infrastructure remains strong but regulatory limitation and lack of professional staff stymies its huge potential, industry experts told a Singapore conference June 15